Blue Water Acquisition Corporation (BLUW) to Combine with Clarus in $216M Deal

Blue Water Acquisition Corporation (BLUW) to Combine with Clarus in $216M Deal

Blue Water (NASDAQ:BLUW) has entered into a definitive agreement to combine with pharmaceutical firm Clarus Therapeutics at an enterprise value of $215.9 million. Clarus provides testosterone replacement therapy (TRT) drugs in an oral pill form under the JATENZO brand and is developing other androgen and metabolic therapies. The combined company is expected to trade on
Read More
To access this post, you must purchase a Monthly or Yearly SPACInsider Subscription, or log in if you're a member.